Cargando…
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, we report the generation and the preclinical evaluation of a...
Autores principales: | Capone, Stefania, Raggioli, Angelo, Gentile, Michela, Battella, Simone, Lahm, Armin, Sommella, Andrea, Contino, Alessandra Maria, Urbanowicz, Richard A., Scala, Romina, Barra, Federica, Leuzzi, Adriano, Lilli, Eleonora, Miselli, Giuseppina, Noto, Alessia, Ferraiuolo, Maria, Talotta, Francesco, Tsoleridis, Theocharis, Castilletti, Concetta, Matusali, Giulia, Colavita, Francesca, Lapa, Daniele, Meschi, Silvia, Capobianchi, Maria, Soriani, Marco, Folgori, Antonella, Ball, Jonathan K., Colloca, Stefano, Vitelli, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062434/ https://www.ncbi.nlm.nih.gov/pubmed/33895322 http://dx.doi.org/10.1016/j.ymthe.2021.04.022 |
Ejemplares similares
-
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
por: Napolitano, Federico, et al.
Publicado: (2020) -
Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
por: Napolitano, Federico, et al.
Publicado: (2021) -
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
por: Agrati, Chiara, et al.
Publicado: (2022) -
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021) -
Tropism of the Chikungunya Virus
por: Matusali, Giulia, et al.
Publicado: (2019)